Open Label Study (Phase III) of NS-32 in Patients with Iron Deficiency Anemia Associated with Gastrointestinal Diseases
Latest Information Update: 06 Dec 2022
Price :
$35 *
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Nippon Shinyaku
- 01 Dec 2022 Results assessing efficacy and safety of intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases, published in the International Journal of Hematology.
- 28 Mar 2022 According to Nippon Shinyaku media release, the Ministry of Health, Labour and Welfare (MHLW) has approved marketing authorization of MonoVer for I.V. injection 500mg/1000mg (ferric derisomaltose/NS-32) for the treatment of iron deficiency anemia based on the results from two Japanese Phase 3 trial for IDA with heavy uterine bleeding, post-partum hemorrhage and this trial.
- 21 Dec 2021 New trial record